Info@ThinkPinkRocks.com

Study provides vital information regarding four diagnostic PD-L1 assays

A pre-competitive consortia of pharmaceutical companies, diagnostic companies, and academic associations, including the International Association for the Study of Lung Cancer, announced phase I results of the “BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT” at the Annual Meeting of the American Association for Cancer Research on April 19.

View article:
Study provides vital information regarding four diagnostic PD-L1 assays

Share

Leave a Reply